India's Biosimilar Norms: Patient Safety Debate Boils Over

A recent panel discussion in India brought to the fore simmering tensions over the country's guidelines on biosimilars, with some panelists suggesting the guidelines compromise on patient safety while other experts sought to tone down any alarmist conclusions.

Post-lunch slots at conferences are usually the ones that are akin to the graveyard shift – the tone is often quiet and even dull, some would say.

But one such session on biosimilars at the recent CPhI Pre-Connect Congress in Mumbai was rather vibrant, with some panelists'...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics